A polar ring endows improved specificity to an antibody fragment

Protein Science

Volumn , Issue , 2016, Pages 1290-1298

  Schaefer, Zachary P ^a   Bailey, Lucas J ^a   Kossiakoff, Anthony A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

antibody engineering; phage display; protein engineering; protein solubility

Indexed keywords

ANTI SILENCING FACTOR 1; ASPARTIC ACID; CHAPERONE; HISTIDINE; IMMUNOGLOBULIN F(AB) FRAGMENT; THREONINE; TYROSINE; UNCLASSIFIED DRUG;

ANTIBODY AFFINITY; ANTIBODY LIBRARY; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ARTICLE; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUOROMETRY; HUMAN; MOLECULAR RECOGNITION; MUTAGENESIS; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN ENGINEERING; SOLUBILITY; X RAY CRYSTALLOGRAPHY;

EID: 84976529626     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1002/pro.2888     Document Type: Article

References (40)

1. Vazquez-Rey M, Lang DA (2011) Aggregates in monoclonal antibody manufacturing processes. Biotechnol Bioeng 108:1494–1508.
2. Perchiacca JM, Tessier PM (2012) Engineering aggregation-resistant antibodies. Annu Rev Chem Biomol Eng 3:263–286.
3. Wang X, Das TK, Singh SK, Kumar S (2009) Potential aggregation prone regions in biotherapeutics: a survey of commercial monoclonal antibodies. mAbs 1.3:254–267.
4. Pepinsky RB, Silvian L, Berkowitz SA, Farrington G, Lugovskoy A, Walus L, Eldredge J, Capili A, Graff C, Garber E (2010) Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis. Protein Sci 19:954–966.
5. Perchiacca JM, Lee CC, Tessier PM (2014) Optimal charged mutations in the complementarity-determining regions that prevent domain antibody aggregation are dependent on the antibody scaffold. Protein Eng Des Sel 27:29–39.
6. van der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, Martinez-Martinez P, Vermeulen E, den Bleker TH, Wiegman L, Vink T, Aarden LA, De Baets MH, van de Winkel JG, Aalberse RC, Parren PW (2007) Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317:1554–1557.
7. Salfeld JG (2007) Isotype selection in antibody engineering. Nat Biotechnol 25:1369–1372.
8. Lee CC, Perchiacca JM, Tessier PM (2013) Toward aggregation-resistant antibodies by design. Trends Biotechnol 31:612–620.
9. Jespers L, Schon O, Famm K, Winter G (2004) Aggregation-resistant domain antibodies selected on phage by heat denaturation. Nat Biotechnol 22:1161–1165.
10. Dudgeon K, Rouet R, Famm K, Christ D (2012) Selection of human VH single domains with improved biophysical properties by phage display. Methods Mol Biol 911:383–397.
11. Trevino SR, Schaefer S, Scholtz JM, Pace CN (2007) Increasing protein conformational stability by optimizing beta-turn sequence. J Mol Biol 373:211–218.
12. Weiss GA, Watanabe CK, Zhong A, Goddard A, Sidhu SS (2000) Rapid mapping of protein functional epitopes by combinatorial alanine scanning. Proc Natl Acad Sci USA 97:8950–8954.
13. Bailey LJ, Kossiakoff AA (2016) Manuscript in preparation.
14. Miller KR, Koide A, Leung B, Fitzsimmons J, Yoder B, Yuan H, Jay M, Sidhu SS, Koide S, Collins EJ (2012) T cell receptor-like recognition of tumor in vivo by synthetic antibody fragment. PLoS One 7:e43746
15. Hornsby M, Paduch M, Miersch S, Saaf A, Matsuguchi T, Lee B, Wypisniak K, Doak A, King D, Usatyuk S, Perry K, Lu V, Thomas W, Luke J, Goodman J, Hoey RJ, Lai D, Griffin C, Li Z, Vizeacoumar FJ, Dong D, Campbell E, Anderson S, Zhong N, Graslund S, Koide S, Moffat J, Sidhu S, Kossiakoff A, Wells J (2015) A high through-put platform for recombinant antibodies to folded proteins. Mol Cell Proteomics 14:2833–2847.
16. Pace CN, Grimsley GR, Scholtz JM (2009) Protein ionizable groups: pK values and their contribution to protein stability and solubility. J Biol Chem 284:13285–13289.
17. Trevino SR, Scholtz JM, Pace CN (2008) Measuring and increasing protein solubility. J Pharm Sci 97:4155–4166.
18. Dudgeon K, Rouet R, Kokmeijer I, Schofield P, Stolp J, Langley D, Stock D, Christ D (2012) General strategy for the generation of human antibody variable domains with increased aggregation resistance. Proc Natl Acad Sci USA 109:10879–10884.
19. Chothia C, Lesk AM (1987) Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol 196:901–917.
20. Moreira IS, Fernandes PA, Ramos MJ (2007) Hot spot occlusion from bulk water: a comprehensive study of the complex between the lysozyme HEL and the antibody FVD1.3. J Phys Chem B 111:2697–2706.
21. Jones S, Thornton JM (1995) Protein-protein Interactions: a review of protein dimer structures. Prog Biophys Molec Biol 63:31–65.
22. Jones S, Thornton JM (1996) Principles of protein-protein interactions. Proc Natl Acad Sci USA 93:13–20.
23. Bogan AA, Thorn KS (1998) Anatomy of hot spots in protein interfaces. J Mol Biol 280:1–9.
24. Jacobs SA, Wu SJ, Feng Y, Bethea D, O'Neil KT (2010) Cross-interaction chromatography: a rapid method to identify highly soluble monoclonal antibody candidates. Pharm Res 27:65–71.
25. Tsai CJ, Lin SL, Wolfson HJ, Nussinov R (1997) Studies of protein-protein interfaces: a statistical analysis of the hydrophobic effect. Protein Sci 6:53–64.
26. Jones S, Thornton JM (1997) Analysis of protein-protein interaction sites using surface patches. J Mol Biol 272:121–132.
27. Sidhu SS, Fellouse FA (2006) Synthetic therapeutic antibodies. Nat Chem Biol 2:682–688.
28. Jespers L, Tonnert TP, Winter G (2004) Selection of optical biosensors from chemisynthetic antibody libraries. Protein Eng Des Sel 17:709–713.
29. Bradbury AR, Sidhu S, Dubel S, McCafferty J (2011) Beyond natural antibodies: the power of in vitro display technologies. Nat Biotechnol 29:245–254.
30. Perchiacca JM, Ladiwala AR, Bhattacharya M, Tessier PM (2012) Aggregation-resistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions. Protein Eng Des Sel 25:591–601.
31. Schaefer JV, Pluckthun A (2012) Transfer of engineered biophysical properties between different antibody formats and expression systems. Protein Eng Des Sel 25:485–506.
32. Bailey LJ, Sheehy KM, Hoey RJ, Schaefer ZP, Ura M, Kossiakoff AA (2014) Applications for an engineered Protein-G variant with a pH controllable affinity to antibody fragments. J Immunol Meth 415:24–30.
33. Bostrom J, Fuh G (2009) Design and construction of synthetic phage-displayed Fab libraries. Methods Mol Biol 562:17–35.
34. Kunkel TA, Roberts JD, Zakour RA (1987) Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol 154:367–382.
35. Huang J, Koide A, Makabe K, Koide S (2008) Design of protein function leaps by directed domain evolution. Proc Nat Acad Sci 105:6578–6583.
36. Minor W, Cymborowski M, Otwinowski Z, Chruszcz M (2006) HKL-3000: the integration of data reduction and structure solution–from diffraction images to an initial model in minutes. Acta Cryst 62:859–866. D
37. Vagin A, Teplyakov A (2010) Molecular replacement with MOLREP. Acta Cryst 66:22–25. D
38. Emsley P, Lohkamp B, Scott WG, Cowtan K (2010) Features and development of Coot. Acta Cryst 66:486–501. D
39. Afonine PV, Grosse-Kunstleve RW, Echols N, Headd JJ, Moriarty NW, Mustyakimov M, Terwilliger TC, Urzhumtsev A, Zwart PH, Adams PD (2012) Towards automated crystallographic structure refinement with phenix.refine. Acta Cryst 68:352–367. D
40. Niesen FH, Berglund H, Vedadi M (2007) The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nature Protoc 2:2212–2221.